Last updated: 2026-09-09 04:29:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Agios Pharmaceuticals, Inc. (AGIO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $33.53, with a market capitalization of $1.98B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $22.24 to $46.00. This page covers its latest market performance, valuation, price trends and company information.
$1.98B | |
$32.53 | |
$138.85 | |
$15.77 | |
$33.10 | |
610.61K | |
1.14M | |
-- | |
$46.00 | |
$22.24 | |
-- | |
-- |
Agios Pharmaceuticals, Inc. (AGIO) last closed at $33.10 as of 2026-09-08 23:31:00, unchanged from the previous close of $33.10.
During the latest regular trading session, AGIO traded between $15.77 and $138.85, with a volume of 610.61K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Agios Pharmaceuticals, Inc. (AGIO) moved from $34.28 to $33.53, representing a decline of 2.18% ($0.75).
The stock traded between $32.23 and $34.93 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 760.81 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 47.5%
AGIO is currently trading at $33.53, placing it 47.5% of the way from its 52-week low of $22.24 to its 52-week high of $46.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 540 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Agios Pharmaceuticals, Inc. (AGIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.